Galapagos in Antiviral Discovery Collaboration with Boehringer Ingelheim | GenomeWeb

NEW YORK, Nov. 11 (GenomeWeb News) - Galapagos Genomics said today that it has entered into a collaboration with Boehringer Ingelheim in the field of antiviral discovery research.

Boehringer Ingelheim will use Galapagos' SilenceSelect platform - a collection of adenoviruses with siRNA-based knockdown sequences targeting over 4,000 human genes -- to perform a genome-wide screen for all drugable genes that influence viral replication in human cells, Galapagos said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.